immunotherapy research

AyuVis Research is developing a platform of immunotherapies using novel small molecules to prevent and treat life-threatening diseases with no current effective therapies, including bronchopulmonary dysplasia (BPD) and pulmonary alveolar proteinosis (PAP). Its small molecules modulate white blood cells to fight inflammation and infection with a balanced immune response, are not hindered by drug resistance, and do not cause immunosuppression. The company reports extensive preclinical research with human clinical trials on the horizon.

preclinical researchsmall molecule drug development

Cellergy Pharma is a privately held biotechnology company founded in 2022 that develops novel CAR T cell products for treating severe atopic allergic diseases. Its patented EMPD and FcεRI chimeric antigen receptors target the cells that produce immunoglobulin E, the cause of all atopic allergic diseases. The company aims to move CAR T cells beyond cancer treatment to diseases caused by the immune system, with a mission to cure severe allergic diseases including uncontrollable severe allergic asthma and severe food allergy.

CAR T cell development

Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient's own immune system. Its lead asset bexmarilimab is a first-in-class anti-Clever-1 antibody being investigated in Phase I/II clinical trials for hematological cancers and solid tumors.

clinical trialsdrug developmentpreclinical development